Gemzar 200mg. 1000mg Injection
PDF Leaflet Revision Date: 04 December 2009
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of locally advanced or metastatic non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, and ovarian carcinoma.
Dosage (summary)
1,000 mg/mu00b2 IV infusion over 30 mins, weekly for 3 weeks, then 1 week rest.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Radiotherapy
Contraindications
- Hypersensitivity to gemcitabine
Common side effects
- Nausea
- Vomiting
- Leukopenia
- Thrombocytopenia
- Anemia
Counselling Points
- Monitor blood counts regularly
- Avoid driving if drowsy
- Report any signs of infection or bleeding
Serious warnings
- Bone marrow suppression
- Increased toxicity with prolonged infusion
Important Disclaimer
The Gemzar 200mg. 1000mg Injection professional information leaflet below is the property of Eli Lilly and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
